Table 3.

Clinical adverse events and laboratory abnormalities.

Parameters	ABT group (N = 93)	NRTI group (N = 99)
Grade 3–4 adverse events	13 (14.0)	11 (11.1)
Serious adverse events	6 (6.5)	3 (3.0)
Drug-related serious adverse events	0 (0.0)	1 (1.0)
Clinical adverse events in ≥2% of patients in either group
Pharyngitis	3 (3.2)	1 (1.0)
Tonsillitis	2 (2.2)	0 (0.0)
Upper respiratory tract infection	4 (4.3)	6 (6.1)
Pulmonary infection	0 (0.0)	2 (2.0)
Urethritis	2 (2.2)	1 (1.0)
Gastroenteritis	0 (0.0)	5 (5.1)
Enteritis	2 (2.2)	0 (0.0)
Diarrhea	8 (8.6)	14 (14.1)
Fever	2 (2.2)	3 (3.0)
Fatigue	2 (2.2)	0 (0.0)
Peripheral edema	0 (0.0)	2 (2.0)
Rash	2 (2.2)	2 (2.0)
Haematuria	1 (1.1)	4 (4.0)
Headache	2 (2.2)	0 (0.0)
Dizzy	2 (2.2)	0 (0.0)
Grade 3–4 laboratory abnormalities in ≥2% of patients in either group
High triglycerides	6 (6.5)	4 (4.0)
High total cholesterol	1 (1.1)	2 (2.0)
High hemobilirubin	0 (0.0)	2 (2.0)
Hepatic function disorder∗	2 (2.2)	1 (1.0)

Data are n (%). ^∗Two or three items increased among aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transferase. ABT: Albuvirtide; NRTI: Nucleoside/Nucleotide reverse transcriptase inhibitor.